var data={"title":"Cisplatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cisplatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5907?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">see &quot;Cisplatin: Drug information&quot;</a> and <a href=\"topic.htm?path=cisplatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cisplatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708671\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cisplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cumulative renal toxicity associated with cisplatin is severe. Other major dose-related toxicities are myelosuppression, nausea, and vomiting.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ototoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ototoxicity, which may be more pronounced in children, and is manifested by tinnitus or loss of high frequency hearing and, occasionally, deafness, is significant.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic-like reactions have occurred. Facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of cisplatin administration. Epinephrine, corticosteroids, and antihistamines have been effectively employed to alleviate symptoms.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Medication safety:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exercise caution to prevent inadvertent cisplatin overdose. Doses greater than 100 mg/m<sup>2</sup>/cycle once every 3 to 4 weeks are rarely used. Care must be taken to avoid inadvertent cisplatin overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21313107\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cisplatin Injection;</li>\n      <li>Cisplatin Injection BP;</li>\n      <li>Cisplatin Injection, Mylan STD</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046356\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Platinum Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046349\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">see &quot;Cisplatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. Cisplatin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>TO PREVENT POSSIBLE OVERDOSE, VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m<sup>2</sup> PER COURSE (eg, every 3 to 4 week cycle). Pretreatment hydration is recommended.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Germ cell tumors:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cushing</i> <i>2004:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 0.7 mg/<b>kg</b> on days 1 to 5 of a 21-day cycle (in combination with bleomycin and etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 20 mg/m<sup>2</sup> on days 1 to 5 of a 21-day cycle (in combination with bleomycin and etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pinkerton 1986: </i>Children and Adolescents: IV: 100 mg/m<i><sup>2</sup></i>on day 1 of a 21-day cycle (in combination with bleomycin and vinblastine or etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lopes 2016:</i> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate risk: PE regimen: IV: 35 mg/m<sup>2</sup> on days 1, 2, and 3 of a 21-day cycle for 3 cycles (weeks 1, 4, and 7) in combination with etoposide; a fourth cycle may be considered depending on response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High risk: PEI regimen: IV: 35 mg/m<sup>2</sup> on days 1, 2, and 3 of a 21-day cycle for 4 cycles (weeks 1, 4, 7, and 11) in combination with etoposide and ifosfamide; a fifth or sixth cycle may be considered depending on response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatoblastoma:</b> Limited data available: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous IV infusion:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;10 kg: PLADO regimen: 2.7 mg/kg/day continuous infusion over 24 hours on day 1 of a 21-day cycle in combination with doxorubicin for 4 to 6 cycles (Pritchard 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 kg and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Monotherapy: Standard risk: 80 mg/m<sup>2</sup>/day continuous infusion over 24 hours every 2 weeks on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Combination therapy: PLADO regimen: 80 mg/m<sup>2</sup>/day continuous infusion over 24 hours on day 1 of a 21-day cycle in combination with doxorubicin (Perilongo 2004; Perilongo 2009; Pritchard 2000) or doxorubicin and sorafenib (Schmid 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermittent infusion (over 6 hours):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;10 kg: 3 mg/<b>kg</b> over 6 hours on day 1 of a 21-day cycle for 4 to 8 cycles in combination with vincristine and fluorouracil or continuous infusion doxorubicin (Douglass 1993; Malogolowkin 2008; Ortega 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 kg and Adolescents: 90 mg/m<sup>2</sup> over 6 hours on day 1 of a 21-day cycle for 4 to 8 cycles in combination with vincristine and fluorouracil or continuous infusion doxorubicin (Douglass 1993; Malogolowkin 2008; Ortega 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Medulloblastoma:</b> Limited data available: Children &ge;3 years and Adolescents: IV: 75 mg/m<sup>2</sup> every 6 weeks on either day 0 in combination with vincristine and cyclophosphamide or day 1 in combination with lomustine and vincristine of each chemotherapy cycle for 8 cycles (Packer 2006; Packer 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Medulloblastoma/PNET, relapsed or refractory:</b> Very limited data available: Children and Adolescents: IV: 60 mg/m<sup>2</sup> on day 0 every 4 weeks (in combination with irinotecan, vincristine, cyclophosphamide, and etoposide) (Kim 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, high-risk:</b> Limited data available: Infants, Children, and Adolescents: IV: 50 mg/m<sup>2</sup> on days 0 to 3 of a 21-day cycle in combination with etoposide (cycles 3 and 5) (Kreisman 2013; Naranjo 2011) or 50 mg/m<sup>2</sup> on days 1 to 4 in combination with etoposide (cycles 3, 5, and 7) (Kushner 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteosarcoma:</b> Limited data available: Children and Adolescents: IV: 60 mg/m<sup>2</sup>/day for 2 days at weeks 2, 7, 25, and 28 (neoadjuvant) or weeks 5, 10, 25, and 28 (adjuvant) in combination with doxorubicin (Goorin 2003) or 120 mg/m<sup>2</sup>/day at weeks 0, 5, 12, and 17 in combination with doxorubicin (Meyers 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>TO PREVENT POSSIBLE OVERDOSE, VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m<sup>2</sup> PER COURSE. Pretreatment hydration is recommended.</b> <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bladder cancer, advanced:</b> IV: 50 to 70 mg/m<sup>2</sup> every 3 to 4 weeks; heavily pretreated patients: 50 mg/m<sup>2</sup> every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ovarian cancer, metastatic:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single agent: 100 mg/m<sup>2</sup> every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Combination therapy: 75 to 100 mg/m<sup>2</sup> every 4 weeks or 75 mg/m<sup>2</sup> every 3 weeks (Ozols 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Testicular cancer, metastatic:</b> IV: 20 mg/m2/day for 5 days repeated every 3 weeks (Cushing 2004; Saxman 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> <b>Note:</b> The manufacturer(s) recommend that repeat courses of cisplatin should not be given until serum creatinine is &lt;1.5 mg/dL and/or BUN is &lt;25 mg/dL and use is contraindicated in preexisting renal impairment. Consult protocols for specific renal impairment dosing adjustments. The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Aronoff 2007:</i> All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Partially cleared by hemodialysis: Administer 50% of dose posthemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Kintzel 1995:</i> Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 46 to 60 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 31 to 45 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, cisplatin undergoes nonenzymatic metabolism and predominantly renal elimination; therefore, dosage adjustment is likely not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151858\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/50 mL (50 mL); 100 mg/100 mL (100 mL); 200 mg/200 mL (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/50 mL (50 mL); 100 mg/100 mL (100 mL); 200 mg/200 mL (200 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151843\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046360\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Cisplatin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pretreatment hydration is recommended prior to cisplatin administration; adequate posthydration and urinary output (&gt;100 mL/hour in adults) should be maintained for 24 hours after administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 6 to 8 hours; has also been infused over 30 minutes to 3 hours, at a rate of 1 mg/minute, or as a continuous infusion; infusion rate varies by protocol (refer to specific protocol for infusion details)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Needles or IV administration sets that contain aluminum should not be used for administration; aluminum may react with cisplatin resulting in precipitate formation and loss of potency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant (at higher concentrations); ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate sodium thiosulfate antidote; elevate extremity. Dimethyl sulfoxide (DMSO) may also be considered an option (See Management of Drug Extravasations for more details).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130931\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151873\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not refrigerate solution (precipitate may form).  According to the manufacturer, after initial entry into the vial, solution is stable for 28 days protected from light or for at least 7 days under fluorescent room light at room temperature. When diluted for administration in D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, <sup>1</sup>/<sub>4</sub>NS, <sup>1</sup>/<sub>3</sub>NS, <sup>1</sup>/<sub>2</sub>NS, or NS, stability is dependent on the chloride ion concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046359\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of metastatic testicular cancer, advanced bladder cancer, and metastatic ovarian cancers (FDA approved in adults); has also been used in the treatment of central nervous system tumors, germ cell tumors, hepatoblastoma, medulloblastoma, neuroblastoma, and osteosarcoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151938\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CISplatin may be confused with CARBOplatin, oxaliplatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Platinol may be confused with Patanol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Cisplatin is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older because of the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cisplatin doses  &gt;100 mg/m<sup>2</sup> once every 3 to 4 weeks are rarely used and should be verified with the prescriber.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151934\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Neurotoxicity (peripheral neuropathy is dose and duration dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrotoxicity (acute renal failure and chronic renal insufficiency)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia (nadir: day 18 to 23; recovery: by day 39; dose related), thrombocytopenia (nadir: day 18 to 23; recovery: by day 39; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Local: Local irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Ototoxicity (as tinnitus, high frequency hearing loss; more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia (mild), ageusia, anaphylaxis, autonomic neuropathy, bradycardia (Schlumbrecht 2015), bronchoconstriction, cardiac arrhythmia, cardiac failure, cerebral arteritis, cerebrovascular accident, dehydration, diarrhea, dysgeusia (Rehwaldt 2009), extravasation, heart block, hemolytic anemia (acute), hemolytic-uremic syndrome, hiccups, hypercholesterolemia, hyperuricemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypotension, increased serum amylase, ischemic heart disease, leukoencephalopathy, Lhermitte's sign, mesenteric ischemia (acute; Morgan 2011), myocardial infarction, neutropenic enterocolitis (Furonaka 2005), optic neuritis, pancreatitis (Trivedi 2005), papilledema, peripheral ischemia (acute), phlebitis (Tokuda 2014), reversible posterior leukoencephalopathy syndrome, seizure, SIADH, skin rash, tachycardia, tetany, thrombosis (aortic; Fernandes 2011), thrombotic thrombocytopenic purpura, vasospasm (acute arterial; Morgan 2011), vision color changes, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151864\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of allergic reactions to cisplatin, other platinum-containing compounds, or any component of the formulation; preexisting renal impairment; myelosuppressed patients; hearing impairment </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151847\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Myelosuppression is a major dose-related toxicity.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Cisplatin is a vesicant at higher concentrations, and an irritant at lower concentrations; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Local infusion site reactions may occur; monitor infusion site during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal events: <b>[US Boxed Warning]: Nausea and vomiting are dose-related toxicities.</b> Cisplatin is associated with a high emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Nausea and vomiting are dose-related and may be immediate and/or delayed. Diarrhea may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions:<b> [US Boxed Warning]: Anaphylactic-like reactions have been reported; may include facial edema, bronchoconstriction, tachycardia, and hypotension and may occur within minutes of administration. Symptoms may be managed with epinephrine, corticosteroids, and/or antihistamines.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperuricemia: Hyperuricemia has been reported with cisplatin use, and is more pronounced with doses &gt;50 mg/m<sup>2</sup>; consider antihyperuricemic therapy to reduce uric acid levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Severe (and possibly irreversible) neuropathies (including stocking-glove paresthesias, areflexia, and loss of proprioception/vibratory sensation) may occur with higher than recommended doses or more frequent administration; may require therapy discontinuation. Seizures, loss of motor function, loss of taste, leukoencephalopathy, and posterior reversible leukoencephalopathy syndrome (PRES [formerly RPLS]) have also been described.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: <b>[US Boxed Warning]: Ototoxicity, which may be more pronounced in children, is manifested by tinnitus and/or loss of high frequency hearing and occasionally deafness; may be significant.</b> Ototoxicity is cumulative and may be severe. Audiometric testing should be performed at baseline and prior to each dose. Certain genetic variations in the thiopurine S-methyltransferase (TPMT) gene may be associated with an increased risk of ototoxicity in children administered conventional cisplatin doses (Pussegoda 2013). Controversy may exist regarding the role of TPMT variants in cisplatin ototoxicity (Ratain 2013; Yang 2013); the association has not been consistent across populations and studies. Children without the TPMT gene variants may still be at risk for ototoxicity. Cumulative dose, prior or concurrent exposure to other ototoxic agents (eg, aminoglycosides, carboplatin), prior cranial radiation, younger age, and type of cancer may also increase the risk for ototoxicity in children (Knight 2005; Landier 2014). Pediatric patients should receive audiometric testing at baseline, prior to each dose, and for several years after discontinuing therapy. An international grading scale (SIOP Boston scale) has been developed to assess ototoxicity in children (Brock 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity:<b> [US Boxed Warning]: Cumulative renal toxicity associated with cisplatin is severe.</b> Monitor serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes (calcium, magnesium, potassium, and sodium) closely. According to the manufacturer&rsquo;s labeling, use is contraindicated in patients with preexisting renal impairment and renal function must return to normal prior to administering subsequent cycles; some literature recommends reduced doses with renal impairment. Nephrotoxicity may be potentiated by aminoglycosides.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Secondary malignancies have been reported with cisplatin in combination with other chemotherapy agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Select dose cautiously and monitor closely in elderly patients; they may be more susceptible to nephrotoxicity and peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Medication safety (usual maximum dose per cycle): <b>[US Boxed Warning]: Doses &gt;100 mg/m<sup>2</sup>/cycle (once every 3 to 4 weeks) are rare; verify with the prescriber. Exercise caution to avoid inadvertent overdose due to potential sound-alike/look-alike confusion between CISplatin and CARBOplatin or prescribing practices that fail to differentiate daily doses from the total dose per cycle. </b> At the approved dose, cisplatin should not be administered more frequently than once every 3 to 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician:<b> [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Adequate diagnostic and treatment facilities and appropriate management of potential complications should be readily available.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hydration: Patients should receive adequate hydration, with or without diuretics, prior to and for 24 hours after administration; serum electrolytes, particularly magnesium and potassium, should be monitored and replaced as needed during and after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299049\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151852\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13162&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May diminish the therapeutic effect of CISplatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: CISplatin may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinorelbine: CISplatin may enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151854\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2523502\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Women of childbearing potential should be advised to avoid pregnancy during treatment. May case fetal harm if administered during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046355\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function tests (serum creatinine, BUN, CrCl), electrolytes (particularly magnesium, calcium, potassium), audiography (baseline and prior to each subsequent dose and following treatment), neurologic exam (with high dose), liver function tests periodically, CBC with differential and platelet count (weekly), urine output, urinalysis, urine specific gravity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151846\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA synthesis by the formation of DNA cross-links; denatures the double helix; covalently binds to DNA bases and disrupts DNA function; may also bind to proteins; the <i>cis</i>-isomer is 14 times more cytotoxic than the <i>trans</i>-isomer; both forms cross-link DNA but cis-platinum is less easily recognized by cell enzymes and, therefore, not repaired. Cisplatin can also bind two adjacent guanines on the same strand of DNA producing intrastrand cross-linking and breakage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151863\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: IV: Rapidly into tissue; high concentrations in kidneys, liver, ovaries, uterus, and lungs </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90% (O'Dwyer 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nonenzymatic; inactivated (in both cell and bloodstream) by sulfhydryl groups; covalently binds to glutathione and thiosulfate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Free drug: 1.3 hours; Total platinum: 44 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Initial: 14 to 49 minutes; Beta: 0.7 to 4.6 hours; Gamma: 24 to 127 hours (O'Dwyer 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;90%); feces (minimal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323068\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CISplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL (50 mL): $21.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL (100 mL): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/200 mL (200 mL): $86.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151868\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abiplatin (IL, NZ, TW);</li>\n      <li>Accocit (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bioplatino (PE);</li>\n      <li>Blastolem (CL, CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Blastolem RU (MX);</li>\n      <li>Cesalin (BD, LK);</li>\n      <li>Ciscan (ID);</li>\n      <li>Cisly (LU);</li>\n      <li>Cispatin (KR);</li>\n      <li>Cisplan (KR);</li>\n      <li>Cisplat (IN);</li>\n      <li>Cisplatin (AU, ID, IN, NZ);</li>\n      <li>Cisplatin Ebewe (HU);</li>\n      <li>Cisplatin medac (LU);</li>\n      <li>Cisplatin Teva (HU);</li>\n      <li>Cisplatin-Ebewe (MY);</li>\n      <li>Cisplatine-Lilly (LU);</li>\n      <li>Cisplatino (CO, EC, PE);</li>\n      <li>Cisplatinum Cytosafe-Delta West (LU);</li>\n      <li>Cisplatyl (FR, KW, QA, SA);</li>\n      <li>Cisteen (PH);</li>\n      <li>Citoplatino (IT);</li>\n      <li>Citoplax (BR);</li>\n      <li>Cysplack (PH);</li>\n      <li>Cytoplatin (LB);</li>\n      <li>Elvecis (AR);</li>\n      <li>Fangtan (CN);</li>\n      <li>Incel (BR, PY);</li>\n      <li>Kemocarb (VN);</li>\n      <li>Kemoplat (IN, PH, SG, TW, UA);</li>\n      <li>Lederplatin (DK);</li>\n      <li>Noveldexis (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Oncotin (PH);</li>\n      <li>P&amp;U Cisplatin (ZA);</li>\n      <li>Placis (ES, JO, TH, TR);</li>\n      <li>Platamine (AE, BH, CY, HR, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Platiblastin (CH, DE);</li>\n      <li>Platicin (LK);</li>\n      <li>Platidiam (BG, CZ, HN, HU, PL, RU);</li>\n      <li>Platimit (HR);</li>\n      <li>Platin (PH);</li>\n      <li>Platinex (BD, HR, IT);</li>\n      <li>Platinol (AR, AT, BE, CH, EE, EG, FI, GR, LU, SE, UY);</li>\n      <li>Platistil (PT);</li>\n      <li>Platistin (FI, SE);</li>\n      <li>Platistine (LU);</li>\n      <li>Platol (ET);</li>\n      <li>Platosin (GB, KR, MY, NL, PK, RO, TH);</li>\n      <li>Platysan (UA);</li>\n      <li>Randa (JP);</li>\n      <li>Sicatem (PY);</li>\n      <li>Sinplatin (BG, RO);</li>\n      <li>Tecnoplatin (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/21947834 /pubmed\" target=\"_blank\" id=\"21947834 \">21947834 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. <i>J Clin Oncol</i>. 2012;30(19):2408-2417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/22547603 /pubmed\" target=\"_blank\" id=\"22547603 \">22547603 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cisplatin [prescribing information]. New York, NY: Pfizer Labs; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cisplatin [prescribing information]. Rockford, IL: Mylan Institutional LLC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cushing B, Giller R, Cullen JW, et al, &ldquo;Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882,&rdquo; <i>J Clin Oncol</i>, 2004, 22(13):2691-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/15226336/pubmed\" target=\"_blank\" id=\"15226336\">15226336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1993;11(1):96-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/8380296/pubmed\" target=\"_blank\" id=\"8380296\">8380296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(2):191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goorin AM, Schwartzentruber DJ, Devidas M, et al, &ldquo;Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651,&rdquo; <i>J Clin Oncol</i>, 2003, 21(8):1574-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/12697883/pubmed\" target=\"_blank\" id=\"12697883\">12697883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hincal AA, Long DF, Repta AJ. Cis-platin stability in aqueous parenteral vehicles. <i>J Parenter Drug Assoc</i>. 1979;33(3):107-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/256991 /pubmed\" target=\"_blank\" id=\"256991 \">256991 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim H, Kang HJ, Lee JW, et al. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients. <i>Childs Nerv Syst</i>. 2013;29(10):1851-1858,<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/23748464/pubmed\" target=\"_blank\" id=\"23748464\">23748464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. <i>J Clin Oncol</i>. 2005;23(34):8588-8596.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/16314621/pubmed\" target=\"_blank\" id=\"16314621\">16314621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kreismann SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomized phase 3 trial. <i>Lancet Oncol</i>. 2013;14:999-1008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/23890779/pubmed\" target=\"_blank\" id=\"23890779\">23890779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo; <i>J Clin Oncol</i>, 1994, 12(12):2607-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/7527454 /pubmed\" target=\"_blank\" id=\"7527454 \">7527454 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(6):527-534.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/24419114/pubmed\" target=\"_blank\" id=\"24419114\">24419114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopes LF, Macedo CR, Aguiar Sdos S, et al. Lowered cisplatin dose and no bleomycin in the treatment of pediatric germ cell tumors: results of the GCT-99 Protocol from the Brazilian Germ Cell Pediatric Oncology Cooperative Group. <i>J Clin Oncol</i>. 2016;34(6):603-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/26729441/pubmed\" target=\"_blank\" id=\"26729441\">26729441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. <i>J Clin Oncol</i>. 2008;26(14):2379-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/18467729/pubmed\" target=\"_blank\" id=\"18467729\">18467729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. <i>J Clin Oncol</i>. 2005;23(9):2004-2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/15774791/pubmed\" target=\"_blank\" id=\"15774791\">15774791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naranjo A, Parisi MT, Shulkin BL, et al, &ldquo;Comparison of <sup>123</sup>I-metaiodobenzylguanidine (MIBG) and <sup>131</sup>I-MIBG Semi-Quantitative Scores in Predicting Survival in Patients With Stage 4 Neuroblastoma: A Report from the Children&rsquo;s Oncology Group,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 56(7):1041-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/21328522/pubmed\" target=\"_blank\" id=\"21328522\">21328522</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Dwyer PJ, Stevenson JP and Johnson SW, &ldquo;Clinical Pharmacokinetics and Administration of Established Platinum Drugs,&rdquo; <i>Drugs</i>, 2000, 59 (Suppl 4):19-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/10864227/pubmed\" target=\"_blank\" id=\"10864227\">10864227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. <i>J Clin Oncol</i>. 2000;18(14):2665-2675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/10894865/pubmed\" target=\"_blank\" id=\"10894865\">10894865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozols RF, Bundy BN, Greer BE, et al, &quot;Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2003, 21(17):3194-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/12860964 /pubmed\" target=\"_blank\" id=\"12860964 \">12860964 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer RJ, Gajjar A, Vezina G, et al, &ldquo;Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma,&rdquo; <i>J Clin Oncol</i>, 2006, 24(25):4202-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/16943538/pubmed\" target=\"_blank\" id=\"16943538\">16943538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar. A Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Chidlren&rsquo;s Oncology Group trial A9961. <i>Neuro-Oncology</i>. 2013;15(1):97-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/23099653/pubmed\" target=\"_blank\" id=\"23099653\">23099653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pegram MD, Pienkowski T, Northfelt DW, et al, &quot;Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer,&quot; <i>J Natl Cancer Inst</i>, 2004, 96(10):759-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/15150304/pubmed\" target=\"_blank\" id=\"15150304\">15150304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. <i>NEJM</i>. 2009;361:1662-1670.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/19846851/pubmed\" target=\"_blank\" id=\"19846851\">19846851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology &ndash; SIOPEL 2. <i>Eur J Cancer</i>. 2004;40(3):411-421.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinkerton CR, Pritchard J, and Spitz L, &ldquo;High Complete Response Rate in Children With Advanced Germ Cell Tumors Using Cisplatin-Containing Combination Chemotherapy,&rdquo; <i>J Clin Oncol</i>, 1986, 4(2):194-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/2418168/pubmed\" target=\"_blank\" id=\"2418168\">2418168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pritchard J, Brown J, Shafford E, et al, &ldquo;Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach--Results of the First Prospective Study of the International Society of Pediatric Oncology,&rdquo; <i>J Clin Oncol</i>, 2000, 18(22):3819-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/11078495/pubmed\" target=\"_blank\" id=\"11078495\">11078495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pussegoda K, Ross CJ, Visscher H, et al; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. <i>Clin Pharmacol Ther</i>. 2013;94(2):243-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/23588304/pubmed\" target=\"_blank\" id=\"23588304\">23588304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ratain MJ, Cox NJ, Henderson TO. Challenges in interpreting the evidence for genetic predictors of ototoxicity. <i>Clin Pharmacol Ther</i>. 2013;94(6):631-635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/24241639/pubmed\" target=\"_blank\" id=\"24241639\">24241639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reece PA, Stafford I, Abbott RL, et al, &ldquo;Two-Versus 24-Hour Infusion of Cisplatin: Pharmacokinetic Considerations,&rdquo; <i>J Clin Oncol</i>, 1989, 7(2):270-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/2536803/pubmed\" target=\"_blank\" id=\"2536803\">2536803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saxman SB, Finch D, Gonin R, et al, &ldquo;Long-Term Follow-Up of a Phase III Study of Three Versus Four Cycles of Bleomycin, Etoposide, and Cisplatin in Favorable-Prognosis Germ-Cell Tumors: The Indian University Experience,&rdquo; <i>J Clin Oncol</i>, 1998, 16(2):702-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/9469360/pubmed\" target=\"_blank\" id=\"9469360\">9469360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmid I, H&auml;berle B, Albert MH, et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. <i>Pediatr Blood Cancer</i>. 2012;58(4):539-544.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/21922643/pubmed\" target=\"_blank\" id=\"21922643\">21922643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang JJ, Lim JY, Huang J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. <i>Clin Pharmacol Ther</i>. 2013;94(2):252-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cisplatin-pediatric-drug-information/abstract-text/23820299/pubmed\" target=\"_blank\" id=\"23820299\">23820299</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13162 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708671\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21313107\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046356\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046349\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F151858\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F151843\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046360\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130931\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F151873\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046359\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F151938\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F151934\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F151864\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F151847\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299049\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F151852\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F151854\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2523502\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046355\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F151846\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F151863\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323068\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F151868\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13162|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">Cisplatin: Drug information</a></li><li><a href=\"topic.htm?path=cisplatin-patient-drug-information\" class=\"drug drug_patient\">Cisplatin: Patient drug information</a></li></ul></div></div>","javascript":null}